This page shows the latest follicular lymphoma news and features for those working in and with pharma, biotech and healthcare.
lymphoma. Follicular lymphoma is the most common type of low-grade non-Hodgkin’s lymphoma, and despite having a median overall survival rate of over 15 years, patients are prone to ... Lenalidomide is a new type of targeted cancer therapy for people
The EU approval clears Polivy for use in combination with chemotherapy drug bendamustine and anti-CD20 rituximab in adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible ... Filings for approval in first-line DLBCL
This includes trials of tafasitamab in non-Hodgkins lymphoma, chronic lymphocytic leukaemia (CLL), relapsed/refractory diffuse large B cell lymphoma (r/r DLBCL) and frontline DLBCL. ... beyond DLBCL, such as follicular lymphoma (FL), marginal zone
However, there is also new competition in the lymphoma market from newcomer BeiGene – the Chinese-drugmaker recently won approval in the US for its MCL therapy Brukinsa (zanubrutinib). ... It is also in clinical development for a host of other blood
and small lymphocytic lymphoma (SLL), taking the fight to AbbVie/Johnson &Johnson’s Imbruvica. . ... The Chinese drugmaker's therapy is also in clinical development for CLL, SLL, follicular lymphoma and marginal zone lymphoma.
China’s BeiGene has claimed its first-ever product approval in the US, getting an FDA nod for its mantle cell lymphoma (MCL) therapy Brukinsa. ... It’s also under regulatory review in China and Europe for MCL, as well as being in clinical development
More from news
Approximately 3 fully matching, plus 57 partially matching documents found.
We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...